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Abstract Magnetic resonance imaging (MRI) has estab-
lished itself as the primary method for local staging in
patients with rectal cancer. This is due to several factors,
most importantly because of the ability to assess the status
of circumferential resection margin. There are several
newer developments being introduced continuously, such
as diffusion-weighted imaging and imaging with 3 T.
Assessment of loco-regional lymph nodes has also been
investigated extensively using different approaches, but
more work needs to be done. Finally, evaluation of tumours
during or after preoperative treatment is becoming an
everyday reality. All these new aspects prompt a review
of the most recent advances and opinions. In this review, a
comprehensive overview of the current status of MRI in the
loco-regional assessment and management of rectal cancer
is presented. The findings on MRI and their accuracy are
reviewed based on the most up-to-date evidence. Optimi-
sation of MRI acquisition and relevant regional anatomy
are also presented, based on published literature and our
own experience.
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Introduction
Magnetic resonance imaging (MRI) has emerged as the
dominant method of pelvic imaging in rectal cancer [1–4],
although MRI is not always available [5]. The main reason
for this dominance is the superb soft tissue contrast between
tumour and other soft tissues on T2-weighted imaging on
MRI, while computed tomography (CT) has difficulties in
this regard [6]. MRI also provides the possibility of
imaging in different planes, although multi-detector CT
can also provide reformatted images.
Multi-disciplinary meetings using MRI have led to
improved possibilities of selecting the most appropriate
treatment for patients with rectal cancer [7–10]. Despite the
apparent advantages, the value of MRI is sometimes
overrated [11–13]. This is due to both misunderstandings
as well as problems with application of the optimal
protocol. In the Magnetic Resonance Imaging and Rectal
Cancer European Equivalence Study (MERCURY), im-
aging workshops were held for participating radiologists
to ensure standardisation of image acquisition techniques
and interpretation of the images [14]. In this, the largest
published study regarding the accuracy of staging of
rectal cancer with the primary objective of assessing the
depth of tumour extension in rectal cancer, T4-staging
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was done accurately in only five out of 14 cases [14].
One of the reasons for staging inaccuracies in everyday
practice is probably the lack of imaging in the optimal
plane [15–17]. One of the aforementioned studies [15]
showed that among patients with a higher inaccuracy of
staging, the number of sequences was higher and imaging
was more commonly performed with gadolinium contrast
enhancement.
The rectum has curvatures both in the right-left
direction and in the antero-posterior direction. In addition,
the rectum ampulla, as the name implies, especially when
filled with a tumour/faeces has a spherical rather than a
cylindrical shape and is thus more difficult to image
perpendicular to its wall than if cylindrical. Finally, the
pelvic floor is formed like a funnel necessitating different
image planes than the three traditional orthogonal planes
for adequate assessment. It can be difficult for non-
specialised MRI technicians to find a rectal tumour and
to anticipate and plan the right imaging planes [18]. Good
study quality, in addition to the inclusion of two
interpreters, results in higher preoperative diagnostic
precision [19].
The sensitivity and specificity of MRI in rectal
tumours with regard to T-staging has also been shown
to be dependent on the experience of the radiologist. In
one study, the sensitivity and specificity of an expert
radiologist were 96% and 74% respectively, while the
same figures for a general radiologist were 77% and 40%
[20].
In this review, we look in detail into the areas where
MRI has improved patient care, and discuss the problem
areas. Several suggestions are provided and areas where
caution should be exercised are highlighted.
Anatomical landmarks
Rectum boundaries
The anal verge marks the lowermost portion of the anal
canal and begins where the skin stops and where the anal
mucosa (anoderm) starts [21]. The anal verge is best
recognised in the sagittal plane (Fig. 1). It can be recognised
as the lowermost portion of the anal sphincter complex. This
can, however, be different on MRI compared with when the
patient is examined by a surgeon who separates the buttocks.
The dentate line is located about 1.5-2 cm upwards from
the anal verge. The dentate line is not visible on MRI, but
occasionally the anal columns can be seen, the lowermost
portion of which corresponds to the dentate line (Fig. 2)
[22]. The dentate line corresponds approximately to the
upper portion of the external sphincter muscle, which can
be inferred on coronally oriented MRI.
The surgical anal canal extends about 3-4 cm, being
shorter in women (2-3 cm), and ends at the anorectal ring
or at the upper portion of the puborectal muscle. The
puborectal muscle is the thicker portion of the pelvic floor
musculature, and is less prominent in women than in men.
The inner muscular wall of the anal canal consists of the
internal sphincter, which is the direct continuation of the
circular layer of the muscularis propria of the rectum. The
outer muscular wall of the anal canal is cranially composed
of the puborectal muscle and caudally of the external
sphincter [22].
The surgical rectum extends for 12-15 cm endoscopically
from the anal verge. The length of the rectum is dependent
on the size of the patients. In tall males the rectum can be 17-
20 cm long and in women less than 15 cm. The exact length
Fig. 1 Mid-sagittal plane turbo
spin echo (TSE) image (a)
(1.5 T) demonstrating lower part
of the external sphincter merg-
ing toward the midline (arrows).
The close-up TSE image (b)
shows the anal verge (white line)
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can be evaluated best on the sagittal plane. However, for
simplicity, 15 cm measured with a rigid sigmoidoscope has
been used as standard. The anatomical definition of the
rectosigmoid junction is based on haustrations. Haustrations
are present in the sigmoid colon and absent in the rectum. In
fact, “rectum” refers to the straight portion of the colon in the
sense that the rectum lacks haustrations. Otherwise the rectum
is much less straight than the name implies. In patients with
diverticular disease of the sigmoid colon, this junction is
appreciated more readily, as diverticula (more accurately
referred to as pseudo-diverticula) denote sigmoid colon and
not rectum. On high-resolution MRI, the rectosigmoid
junction is the location where the rectum becomes completely
covered by peritoneum. This is appreciated ventral to the
rectum where the peritoneal reflection is detected. The
rectosigmoid junction is orientated obliquely towards the
sacrum. The peritoneal reflection is sometimes located more
distally in women with a deep Douglas pouch, than in men
[23]. In summary, the upper distinction of the rectum is 15 cm
above the anal verge based on the rigid sigmoidoscope as
most previous studies have used this definition. However, the
radiologist should inform the members of the multidisciplin-
ary team when a tumour originates from a mobile portion of
the colon with a mesentery root, as this may be of relevance
for the radiation target.
Surrounding the rectum, there is a layer of fat, the
perirectal or the mesorectal fat. There is less fat anterior
and caudal to the rectum than to the other sides [24]. The
amount of perirectal fat is larger in men and correlates
with the visceral compartment area, but not the body’s
cross-sectional area, body mass index or age [25].
Although the total amount of fat has not been shown to
influence the accuracy of tumour staging [26], it is
conceivable that the small distance between structures
ventral to the rectum can make analysis of tumour growth
assessment ventrally difficult [27]. The perirectal fat is
often referred to as “mesorectum”. The mesorectum is
carpeted behind and laterally by a postero-lateral fibrous
envelope belonging to the pelvic visceral fascia and
ventrally by a recto-genital membrane of variable nature
corresponding to “Denonvilliers’ fascia” [28]. Denonvil-
liers’ fascia covers the dorsal aspect of the prostate and
seminal vesicles in men [29]. This fascia is fused to the
mesorectal fascia as it concerns MRI. The mesorectal or
perirectal visceral fascia (Fig. 3) has gained great
importance as it pertains to rectal cancer surgery when
total mesorectal excision (TME) was introduced. Tumours
located close to this fascia are considered to threaten the
fascia [30]. What constitutes a safe distance is, however, not
Fig. 2 TSE image (1.5 T) demonstrates alternating protruding mucosa
and impressions corresponding to anal columns (white arrows)
Fig. 3 Axial TSE image (a)
(1.5 T) shows separation of the
mesorectal fascia (white solid
arrow), otherwise known as the
perirectal visceral fascia, from
the parietal pelvic fascia (dotted
arrow). This is due to tumour in
the upper portion of the utero-
sacral ligament (black arrow)
shown on the higher axial TSE
image (b)
Insights Imaging (2010) 1:245–267 247
ascertained. A distance <1 mm is definitely associated with
risk of involvement of the surgical circumferential resection
margin (CRM). Distance <2-5 mm has also been suggested
as indicative of a threatened margin with a greater risk of
recurrence. Obviously, the larger the safe margin the less
likelihood of false-negative results, however at the expense
of low specificity. Also, adopting a larger safe margin would
lead to classifying most anterior and low tumours as
potentially threatening the fascia. At most centres, 1 mm is
considered the safe distance. Care should be exercised not to
confuse the CRM and mesorectal fascia with one another.
CRM is a surgical term and can be intentionally or
inadvertently inside or outside the mesorectal fascia.
What the surgeon and/or oncologist need(s) to know
For optimal preoperative treatment planning of rectal
cancer, adequate local staging is of paramount importance
[30]. Factors associated with prognosis are tumour height,
T-stage, extramural tumour growth, lymph node status,
vascular and neural invasion, threatened CRM and over-
growth to adjacent structures. In addition, narrow obstetric
conjugate and shorter interspinous distance appear to be
factors leading to poor surgical quality [31].
There are differences in how surgeons, oncologists and
therapeutic radiologists treat patients. There is growing
support for treatments being employed before surgery as
opposed to after surgery. The former has been employed in
Europe for some time now, and it seems to be becoming the
dominant approach even in the US. At our institution,
postoperative treatment is mostly part of salvation therapy,
given only very rarely. In Europe tumours are generally
divided into three categories based on radiological findings
into “good” (those with the best prognosis and therefore no
need for preoperative neoadjuvant therapy), “bad”
(tumours that require only short-term preoperative neo-
adjuvant therapy) and “ugly” (tumours in need of more
extensive preoperative neoadjuvant therapy). There are
some minor differences between different institutions as to
what constitutes good, bad or ugly, but most authors
consider T1-2 N0 tumours as good and any tumour
threatening/involving the mesorectal fascia or T4 as ugly.
The areas of differences are the following:
& N1 tumours are considered sometimes by some authors as
part of the good group, and by others as a sign of the bad
group. If a malignant lymph node threatens the mesorectal
fascia, however, the classification should be ugly.
& Signs of vessel invasion have been used for up-front
chemotherapy by some or classification as a sign of the
bad group by others.
& Some consider small T3 tumours (T3a, or T3a-b) as
good.
Below, the most important of these factors will be
discussed. Before reading the following sections, we would
like to emphasise two points:
First, one should avoid staging for lesions that are not
definitely cancers. T-staging is only for adenocarcinomas
and not benign polyps or other tumours. While experienced
clinicians might discover this, inexperienced clinicians in
cases of inadequate biopsies might not understand the
limitations of MRI and consequently make a diagnosis of
cancer.
Second, for anal cancers (squamous cell carcinomas) the
staging system is completely different from that of low
rectal tumours. The same applies to metastases from other
primaries to the rectum. There are some clues to differen-
tiate rectal cancers from other tumours. Discussion of these
signs is beyond the scope of this article; however,
calcification, mucin production, circumferential growth
and mucosa ulceration are more commonly seen in
adenocarcinomas than in other malignancies.
T-stage
T-staging is based on the tumour relationship to the
muscularis propria layer, and invasion of neighbouring
organs. The muscularis propria is demonstrated as a thin
lower signal layer surrounding the rectum (Fig. 4).
Fig. 4 Axial TSE image (1.5 T) of the pelvis at the level of a mid-
rectal cancer. The intact muscularis propria is seen as a thin dark band
on the left side where no tumour is present (solid arrow). The
mesorectal fascia is also marked by the dotted arrows. Both the
muscularis propria and the mesorectal fascia are visible as a thin low-
signal layer and line, respectively. However the imaging plane should
meet these structures perpendicularly for optimal demonstration
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T-staging in rectal cancer [according to UICC (Interna-
tional Union Against Cancer) TNM5] is classified in the
following manner:
TX: not determined
T0: no visible tumour
Tis: carcinoma in situ
T1: submucosal tumour only (Fig. 5)
T2: growth into the muscularis propria.
T3: growth into the perirectal fat
T4: growth into neighbouring organs, or perforation
(Fig. 6)
– (a) Other organs, excluding peritoneum
– (b) Peritoneum (T4 a and T4b are reversed in
TNM versions 6 and 7)
If the radiologist intends to use TNM staging, it is
important that the clinicians and the radiologist have an
understanding of which version of TNM is employed.
Clearly, the TNM staging system is lagging behind on
several grounds [32], including what constitutes neighbour-
ing “organ” structures. The major pelvic vessels, the pelvic
parietal fascia (the fascia covering lateral extraperitoneal
structures mainly consisting of major pelvic vessels) and
the mesorectal fascia are not considered “organs”. The
status of the pelvic floor musculature is not explicitly
mentioned as neighbouring organs. Therefore, care should
be taken to convey the information to clinicians in the most
appropriate manner. Another issue that might be confusing
to a radiologist is that a rectal cancer can grow into a
structure covered by peritoneum, such as the small bowel or
corpus uteri, without actually involving the peritoneum.
Most studies have concentrated on T-staging accuracy
with moderate-good results [33]. The problem with these
studies, however, is that they mostly include T2 and T3
cases and relatively few T4 and T1 cases. The reported total
MRI diagnostic accuracy is 66-88% [6, 11, 13, 15, 21, 26,
30, 34–36].
In order to have the best assessment of T-staging and
particularly the distinction among T1, T2 and “early” T3,
the plane of imaging should be perpendicular to the
muscular layer at the location of the largest tumour burden
in order to overcome problems with partial volume effect.
This may not be necessary with large T3 tumours, unless
these tumours are closer to the mesorectal fascia at a
location other than where they have the largest tumour
extension. In these cases, assessment of mesorectal fascia
takes precedence and should be evaluated with the
appropriate plane of imaging. Our experience from studies
with a total of more than 900 cases with histopathological
information is that several signs should alert the radiologist
to look more intensively for extramural tumour growth (T3)
when the following are present:
& Tumour ulceration
& Tumour larger than semi-circumferential
& Long tumours
& Malignant lymph nodes
& Distant metastases
Tumours tend to extend beyond the muscular layer at
their centre, both in the longitudinal plane, parallel to the
rectum, and in the plane perpendicular to the rectum. This
rule does have exceptions. Some tumours, especially large
ones and mucin-producing tumours, can extend through the
muscularis propria at several locations.
For adequate assessment of tumour growth into neigh-
bouring structures and organs, imaging should be done in
the plane that demonstrates the smallest distance between
the tumour, on the one hand, and the neighbouring organ
and/or the mesorectal fascia, on the other hand. Demon-
stration of fat between the tumour and neighbouring
Fig. 5 True transversal TSE
image of the pelvis (a) (1.5 T)
demonstrates a small tumour
(arrow). High-resolution TSE
image with thin slice (3 mm)
perpendicular to the muscular
wall (black arrow) shows a T1
tumour (b)
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structures is evidence of non-involvement. Absence of fat,
however, does not necessarily indicate tumour invasion. If
nearly simultaneous or later CT of the pelvis is obtained, it
is prudent to study the CT as well. It is not infrequently
seen that a structure lying close to the tumour with virtually
no intervening fat on MRI, is seen separated from the
tumour by fat on CT. The best signs for growth of rectal
cancer into neighbouring organs are nodular growth into the
neighbouring organ or causing obstruction (e.g. hydro-
nephrosis) [15]. Retraction of fasciae is considered a sign of
tumour growth by some authors, yet it does come with
exceptions.
Tumour perforation is classified as T4 according to the
TNM classification. Abscesses are usually limited by the
mesorectal fascia.
Small tumour spiculations can contain tumour cells.
Tumours have a tendency to grow along fasciae and nerves
stretching to other structures not primarily close to the
tumour (Fig. 7). Tumours with high mucin content can also
cause problems. Occasionally, mucin fills out and replaces
the whole mesorectal fat. On T2 weighted imaging,
especially with shorter echo time (TE), the contrast between
the fluid-like signal of the mucin and fat could be lost
(Fig. 8). In our experience, T1-weighted imaging, simulta-
neous CT or great experience of the radiologist can
overcome this problem. Another solution could be higher
TE with TSE images, which leads to larger T2 weighting
and thus makes mucin appear brighter than fat (Fig. 8). It is,
therefore, wise to have one plane of imaging with higher
TE.
Distance to the mesorectal fascia
The distance to the mesorectal fascia is the single most
important local prognostic factor. When the distance on
preoperative MRI is small, the risk of involved CRM is
increased considerably [33]. It has been suggested that by
applying MRI for the selection of whether preoperative
treatment should be given or not before optimal surgery, the
frequency of neo-adjuvant treatment, with its acute and late
adverse effects, can be as low as 30-35% without reduction
of pathologically CRM-negative resection specimens [37].
CRM positivity conveys a great risk of both local and
distant failure, being the relevant clinical endpoints.
However, it has been shown that the greatest relative
effects of preoperative radiotherapy are when the distance
to the CRM is the greatest [38]. As mentioned above, what
constitutes a threatened margin has been the subject of
several studies and the lower the threshold, the higher the
sensitivity at the cost of specificity. At most centres, a
margin of 1 mm is considered the threshold, yet others have
chosen other thresholds [39–41]. In order to obtain the best
results both the imaging plane and the slice thickness of the
imaging on T2-weighted imaging should be optimised in
the same way as when involvement of other neighbouring
structures is studied. In the MERCURY study, 93% of the
studies were technically satisfactory and among these, the
Fig. 7 Semi-coronal plane TSE image (1.5 T) showing tumour (solid
arrow) growing along the side mesorectal fascia (dotted arrow)
Fig. 6 Axial (a) and sagittal (b)
plane reformatted images from
original sagittal three-
dimensional (3D) T2-weighted
images (3 T) show a rectal
cancer (white arrow) growing
into an adjacent small bowel
loop
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specificity for prediction of a clear margin was 92% [14,
42]. Others have reported an accuracy rate of 88% [43].
Ability to assess the potential endangerment of the
mesorectal fascia has been the most important prognostic
indicator. As the mesorectal fascia is very thin, it is
mandatory to have an imaging plane perpendicular to this
fascia in case of possible tumour encroachment. Once
again, we would like to emphasise that what the radiologist
evaluates is threatening or involvement of the mesorectal
fascia. Involvement of the CRM is decided at surgery,
because the CRM is defined after surgery.
Interestingly, both T1-weighted images and CT can give
the same information in locations where there is enough fat
between the rectum and the mesorectal fascia as long as we
can differentiate between the tumour and the rectal wall
based on other information. This is due to the fact that both
T1-weighted images and CT provide excellent contrast
between tumour tissue/mesorectal fascia and fat. It is
perhaps not surprising that low and anterior rectal tumours
are associated with overestimation of the involvement of
the mesorectal fascia on MRI [27]. One should, however,
note that the least distance between the tumour and the
mesorectal fascia is measured at points where the tumour
extends beyond the muscularis layer. Therefore, T1 and T2
tumours do not have threatened resection margins per
definition, except in the anal canal. Moreover, the distance
between T3 tumours and the fascia should be measured at
the location where the tumour extends outside the muscular
propria layer as mentioned above. Pushing of neighbouring
organs and proximity are unspecific signs of tumour
overgrowth.
Administration of rectal enema can affect the distance
between the tumour and the mesorectal fascia [44], yet
there are no studies that have looked at whether assessment
of CRM status (threatened/involved or not) is influenced. In
CT colonography, sufficient filling of the rectum can lead to
effacement of the rectal wall and mesorectal fascia. This
could mean that the distance to the mesorectal fascia is not
fixed but variable to some extent. Large polypoid luminal
tumours can often expand the rectum and can infrequently
not be diagnosed as threatening the fascia or even classified
as T4 tumours.
N-stage
The presence of malignant lymph nodes adversely affects
the prognosis. Generally, in gastrointestinal tumours N-
stage is not influenced by the location of lymph nodes but
mainly by the number of regional metastatic lymph nodes.
For rectal cancer, one to three malignant nodes in the
perirectal fat denote N1 stage, while more than three
malignant nodes denote N2 stage. These classifications
have been modified in TNM7, with subclasses defined
based on smaller subgroups with a different number of
malignant nodes. N1 is still metastasis in one to three
regional lymph nodes, with N1a metastasis to one node,
N1b metastasis to two to three nodes, and N1c is metastatic
satellites in subserosa, without recognisable nodal struc-
tures. N2 is metastasis in four or more regional lymph
nodes, with N2a in four to six nodes and N2b in seven or
more. We still apply TNM version 5 at our centre, yet it
would be prudent for radiologists to try to provide the
number of nodes they deem malignant so that confusion is
avoided.
Many studies have looked at whether MRI can detect the
presence of lymph node metastasis (N0 vs other N-stages).
These studies, based primarily on lymph node size, have not
shown very high accuracy rates (70-76%) for the diagnosis
of presence of malignant lymph nodes [45–48].
During the past decade the attention in the radiology
literature has shifted towards the appearance of individual
Fig. 8 Axial (a) and semi-axial
(b) TSE images (1.5 T) of a
mucin-producing tumour. The
first image (a) with higher TE
(120 ms) produces a stark con-
trast between fluid/mucin (stars)
and fat. Both the urine in the
urinary bladder (large star) and
the tumour mucin (small star)
have higher signal than the
surrounding fat. The urinary
bladder was emptied and the
patient imaged with lower TE
(80 ms). There is very little
contrast between mucin and fat,
or between urine and fat
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nodes. Some cancers, such as rectal and prostate cancers,
tend to have infiltrative lymph node metastasis. In these
patients the malignant nodes do not enlarge early on and in
fact most malignant nodes are small in rectal cancer.
Several studies have looked at the contour and homogene-
ity of the lymph nodes [49, 50]. Despite promising initial
results, probably due to assessments of only larger nodes,
later studies have failed to replicate the same success [51].
Node calcification, seen best on CT, should be interpreted
as carrying a high risk of malignancy in the setting of rectal
cancer, just like calcification anywhere else. Gadolinium
has also been used for lymph node staging, although the
accuracy rates have similarly been around 70% [52]. There
are no studies that have combined the pattern of gadolinium
enhancement and lymph node morphology to see if lymph
nodes assessment is improved.
More recently, several studies have focused on ultra-
small superparamagnetic iron oxide (USPIO) particles with
promising results [53]. The mechanism of action is uptake
of USPIO by scavenger cells present in normal lymph
nodes. This leads to loss of signal on T2- and especially
T2*-weighted imaging. Nodes with malignancy replacing
normal cells are not affected. The estimated percentage of
the white region (i.e. areas without loss of signal, and
therefore no uptake of USPIO) and measured ratio are the
most accurate and most practical criteria for predicting
malignant nodes [54]. Despite promising results, the Food
and Drug Administration (FDA) of the United States has
not approved the application for routine clinical use, and
consequently the manufacturer has withdrawn its applica-
tion to the European Medicines Agency. This places some
serious doubt on the future of this agent. Furthermore,
USPIO requires administration the day before, with
imaging the following day. Also, image interpretation
demands a learning curve. This could mean that, even if
approved, there might be some time before this agent, if
ever, is widely used in Europe or the US.
Diffusion-weighted imaging (DWI) has been suggested
as a method for the assessment of malignancy in lymph
nodes. DWI shows differences between tumour tissue and
non-malignant tissue because of higher cell density in
malignancies. However, there is a great degree of overlap
between malignant and benign nodes; therefore, the
clinical implications of DWI are at present unclear. In
gynaecological tumours, the diffusion-perfusion fraction
or correlating apparent diffusion coefficients (ADC) of the
nodes with the ADC of the tumour as an adjunct to the
size criteria has improved lymph node staging. This
approach has not been used for rectal cancer yet, nor has
it been validated by more studies for gynaecological
tumours. More on diffusion can be found later in this
article [55].
New hope is emerging for ultra-thin T2-weighted
imaging (Fig. 9). Studies using this method are ongoing at
our centre with initial promising results. The basis of this
method is basically the same as above regarding lymph
node morphology. We have been able to assess even
smaller nodes using the same criteria and find malignant
nodes with more confidence. It is not known if the
diagnostic accuracy regarding N-staging will significantly
increase.
Another potentially promising approach could be spe-
cific intravascular contrast agent bound to albumin. This
contrast agent seems to be limited to normal vessels and not
the abnormal vasculature of a malignant tumour. There is
hope that this agent might help distinguish areas of focal
chronic pancreatitis from pancreas cancer. Moreover, this
agent has been used in ten patients and has shown
enhancement of normal lymph nodes or non-tumour-
involved parts of the lymph nodes [56].
Fig. 9 Tumour (solid arrow) in
the upper rectum shown on
traditional TSE on sagittal plane
(a) and thin-slice 3D T2-
weighted sagittal image (b) both
on 3 T MRI. The anterior lymph
node (hatched) is more clearly
depicted on the thinner slice
(1 mm). Additionally, one can
see that this node is irregular in
contour and involves the perito-
neum (dotted arrows) behind the
uterus
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Whatever method used, one has to remember that a
lymph node is a complex structure and malignancy in a
lymph node does not always uniformly change the node.
A lymph node can harbour micrometastasis or minimeta-
stasis. Lymph node involvement can be patchy. Another
important issue is that not all malignant mesorectal
lymph nodes have the same prognostic importance. As
outlined above, subserosal metastases are prognostically
more important than up to three malignant mesorectal
lymph nodes according to TNM7. Also, a malignant
lymph node deep inside the mesorectal fascia will not
adversely affect surgical outcome as much a malignant
lymph node lying on the mesorectal fascia could because
the latter could potentially threaten the fascia and
consequently the CRM.
Most nodes in patients with rectal cancer are located in
the laterodorsal part of the mesorectum, with no difference
in distribution between malignant and benign nodes. The
majority of positive nodes are located at the level of the
tumour or above it. There are significantly more benign
nodes located below the tumour than malignant nodes. Low
rectal or anorectal tumours are at potential risk of
metastasising to the pelvic side walls and occasionally
inguinal lymph nodes [57], yet embryology does not
always dictate metastatic pathways [58].
There is some controversy regarding how to handle
metastatic lymph nodes in the pelvic side walls. In Japan,
removal of these nodes is considered essential in the
curative treatment of selected patients, whereas in Western
Europe these sites are covered by radiation. In Western
Europe, involved nodes are generally considered as signs of
distant metastatic disease [59–61], at least in tumours above
the peritoneal recess. Not infrequently, we see malignant
lateral pelvic lymph nodes clearly along the drainage of the
middle rectal and obturator vessels. Malignancy in the
lateral pelvic nodes in the absence of a low locally
advanced rectal cancer should lead to a search for other
malignancies (e.g. prostate, Fig. 10).
We are still a long way from the accurate assessment of
lymph nodes. Many patients receive preoperative treatment
making the correlation between MRI before treatment and
histopathology rarely possible. Suspected lymph node
metastases are a strong indication for preoperative treat-
ment. Moreover, we need to know that we are correlating
the correct lymph nodes. This is particularly important for
a lymph node close to the resection margin. If a node lying
close to a future resection margin is malignant, the
treatment strategy could be greatly influenced. Also, very
small lymph nodes can be malignant nodes that we might
not even be able to detect with at least some of the
methods mentioned above. Finally, a lymph node com-
pletely replaced by tumour or mucin could cause inter-
pretation problems for the pathologist. Most pathologists
wish to see some remaining lymph node tissue to
distinguish a malignant lymph node from an extramural
metastasis. This has caused controversies in proper N-
staging and also influenced the definitions in the TNM
systems [62].
Fig. 10 Axial TSE images (1.5 T) of a rectal cancer originating from the right rectal wall (white arrow). There is a malignant lymph node (black
arrow) in the obturator fossa on the left side. The cause of the malignant lymph node is the prostate cancer (dotted arrow)
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Tumour height and tumour size
The tumour height is measured from the anal verge up
until the lowermost portion of the tumour shows
attachment to the wall. On MRI, the distance is measured
on a line drawn on the sagittal plane. This distance could
be different from the one measured on a straight rigid
rectoscope, but in our experience the difference is seldom
larger than 1 cm. Tumour height defines if a tumour is a
rectal cancer or a sigmoid cancer. The limit used for this
purpose varies between countries from 10 to 15 cm. In the
axial plane, the rectum finishes below the S1-2 disc [24,
26]. Coincidentally the upper limit of what constitutes the
rectum (i.e. 15 cm from the anal verge) in Western Europe
is the largest surgical definition of the rectum that we
know of.
A tumour that begins within 5-6 cm of the anal verge is
considered a low rectal cancer and is associated with a
higher risk of recurrence [39, 63]. Low rectal tumours can
be difficult to assess on MRI and, therefore, a novel staging
system for these tumours is suggested (Fig. 11) [64]. This
classification is based on the fact that tumours growing into
or beyond the intersphincteric plane on MRI have a higher
likelihood of positive CRM even after preoperative treat-
ment [65]. The more simplified approach could improve
reproducibility.
For assessment of tumour size, the best single variable is
the length of the tumour [66]. Measuring tumour volume
offers better correlation with histopathology than tumour
length; however, volume measurement is more cumber-
some. Tumour diameters are subject to more variation than
tumour volume. When measuring tumours, one should
remember that the luminal polypoid part of the tumour is
prone to slough off, especially after treatment. It is not
uncommon that these tumours are initially over-staged as
T3 or T4 because of expansion of the rectum and problems
with imaging. After preoperative treatment, the limited
growth of these tumours is seen because of the sloughed
luminal portion. To assess the extramural growth of these
tumours, one should focus on the pedicle and the
extramural portions of the tumours.
Neurovascular invasion
Extension along nerves and extramural intravascular
growth are associated with a worse prognosis. Extension
along nerves, especially tiny neural branches, is not easily
seen on MRI. We have occasionally seen tumour extensions
in the form of thick nodular bands extending towards the
sacral neural foramina or lumbosacral nerves. Extension
along the lateral mesorectal fascia close to hypogastric
nerves should raise suspicion of neural growth.
Intravascular extension is, however, easier for the
radiologist to diagnose (Fig. 12). Tumours usually grow
along vessels. However, this perivascular growth is not
always equal to intravascular growth. A new system has
been proposed for the assessment of intravascular growth
[67, 68]. According to this scoring system for intravascular
growth assessment, the more signs present the higher
likelihood of intravascular growth. These signs are nodular
growth at the site of extramural growth, vessel in proximity
to the tumour, vascular enlargement and vessel signal
heterogeneity. The authors of the mentioned studies have
found that when more than two signs are present, the
prognosis is similar to when tumours have intravascular
growth histopathologically.
Imaging with 3 T and variable flip angle ultra-thin 3D
makes the distinction of vessels easier because of infinite
ET leading to normal vessels having a more homogeneous
Fig. 11 Coronal images of two
low rectal tumours. In one case
(a, reformatted from original
sagittal 3D T2-weighted image,
3 T), the tumour obliterates the
intervening fat (black arrow)
between the pelvic floor and the
rectal lumen. In the other case
(b, TSE image, 1.5 T), the
intervening fat is preserved
(white arrow)
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signal pattern. The extension through the muscular propria
appears to occur predominantly where the vessels enter the
rectum, a location where the muscular coat is also absent.
Extramural tumour growth or depth
Extramural depth (EMD) is the tumour extension into the
mesorectal fat in T3 tumours. It is measured in millimetres on
a line perpendicular to the rectum. A classification system has
been adopted at several centres based on the extension of
EMD outside the muscular layer. T3a is a T3 tumour with
EMD <1 mm, T3b≥1 mm and <5 mm, T3c ≥5 mm and
<15 mm, and T3d ≥15 mm. The same system is also used for
colon cancer.
The MERCURY study [14] showed that MRI provides a
non-biased estimation of EMD, the latter being an important
prognostic factor [69]. The 95% range of over- and
underestimation of EMD was about 4-5 mm compared with
histopathology [70, 71]. It is possible that the figure of 4 mm
is a reflection of slice thickness [72]. Another smaller study
has also demonstrated good correspondence between histo-
pathology and MRI for measurement of EMD (Fig. 13) [73].
Of all patients with rectal cancer who undergo pre-
operative MRI staging, about half will have features
indicating a good prognosis (T1-T3a-b, N0, no vascular
invasion, clear CRM) and may safely undergo primary
TME [4, 39], although others advocate neo-adjuvant
therapy for all T3N0 tumours [74]. Nevertheless, the
decision to give neo-adjuvant therapy can be decided based
on EMD, provided there is no endangerment of the
mesorectal fascia or nearby organs, and if there are no
malignant lymph nodes or signs of intravascular growth.
This places great pressure on the radiologist to ascertain the
exact EMD in T3 tumours. As mentioned above, 95% of
the results in the MERCURY study were within 4-5 mm of
the histopathological measurements. If the multidisciplinary
team wants to base the decision to administer preoperative
therapy based on EMD, then he/she must take into account
the possibility of some T3a and T3b tumours being
misclassified as T3c and vice versa. To solely rely on
EMD is not correct, as other factors like tumour height
from the anal verge, whether the tumour is anterior, lateral
Fig. 12 Sagittal plane TSE image (3 T) showing rectal tumour with
intravascular growth (arrow). The vessel is expanded, irregular,
showing tumour signal and is close to the tumour
Fig. 13 Measurement of extramural tumour growth is dependent on
the plane of imaging. True transverse TSE (a, 3 T) image shows the
extramural tumour growth to be 9 mm (white line). Reformatted image
from original 3D T2-weighted images with plane reconstructed
perpendicular to the rectal wall (b, 3 T) shows that the extramural
tumour component can be 20 mm (dotted line)
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or posterior and size of the mesorectum are also relevant to
consider. We presently do not have precise knowledge of
the relevance of each factor. Thus, the experience of the
team is important. This experience can only develop if there
is immediate follow-up after surgery with histopathology
and later follow-up of clinical outcome.
MRI protocols
It is customary in most radiological review articles to begin
with the MRI protocol. We chose, however, to begin with
what the radiologist should report in order to make it easier
to understand what the MRI protocol should consist of and
the reason for this.
The indications for MRI of the pelvis in patients with
rectal cancer are:
1. To evaluate the local extent of the tumour, before or
perhaps also during/after preoperative treatment.
2. Local recurrence can also be an indication for MRI.
This will be dealt with below.
3. Finally, sometimes MRI is used for a definitive
diagnosis of rectal cancer (see above).
The basis for local assessment of rectal cancer is T2-
weighted imaging with turbo spin echo (TSE) [75]. This
imaging should be performed in appropriate planes (Fig. 14).
There is, however, no consensus about what are the essential
planes, yet two requirements should be fulfilled: wherever
distinction among T1, T2 and minimal T3 is important the
imaging should preferably be perpendicular to the rectal
wall, and whenever growth into neighbouring organs/tissues
is not certain the imaging plane should be such as to show
the smallest intervening fat (Table 1).
Sagittal plane imaging provides the best plane for
assessment of growth into structures and organs anterior to
the rectum where, especially in the female pelvis, the
distance between the rectum and these structures is the least.
For low rectal tumours, imaging semi-coronally, perpen-
dicular to the pelvic floor, which is often the same as parallel
to the anal canal, provides very good depiction of the pelvic
floor and the anal canal. Unfortunately, this is sometimes
replaced with orthogonal coronal plane imaging, which is
not the same.
Tumours from the ampulla of the rectum, especially
polypoid tumours, growing dorsally and laterally, may be
difficult to interpret. Because of the funnelled shape of the
pelvic floor, adequate assessment is difficult on sagittal,
orthogonal coronal or axial planes.
Three-dimensional imaging might overcome the problem
of multiple imaging planes, saving time [76, 77].
At some institutions, the distinction between T1, T2 and T3,
especially in polypoid tumours, is solved by imaging in a plane
perpendicular to the pelvic floor or administration of different
types of rectal enema which expand the rectum [78, 79].
T1-weighted imaging seldom leads to increased infor-
mation for experienced radiologists. Its use, however, does
not increase imaging time considerably and may occasion-
ally help with other diagnoses. Mucin-producing tumours
might be better visualised with T1-weighted imaging
compared with T2-weighted imaging with lower ET.
Contrast-enhanced imaging with gadolinium does not
improve local staging [80]. Contrast-enhanced imaging
only adds adverse effects and increases imaging time.
Perfusion studies (see below) with both MRI and CT
appear to provide information similar to 18F-fluorodeox-
yglucose (FDG)-positron emission tomography (PET)
[81]; i.e. tumours with increased perfusion and metabo-
lism are more likely to respond to preoperative (chemo-)
radiotherapy (see below).
DWI has attracted much attention recently. DWI could
help to detect tumours similar to other abdominal malig-
Fig. 14 Value of imaging in
other planes. The axial TSE
image (1.5 T) (a) shows a
tumour that might be interpreted
as a small T3. The coronal TSE
image, however, shows no
extramural tumour growth.
The tumour was a T2 at
histopathology
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nancies [82–84]. DWI cannot be used to confirm malig-
nancy. DWI might also predict which patients have a higher
likelihood of responding to treatment [85]. This, however,
does not help treatment planning for the individual patient.
Field strength
More studies are coming regarding the accuracy of 3 T,
sometimes with and sometimes without comparison with
1.5 T. The reported overall accuracy rate of T-staging with
3 T for rectal cancer has been 85-92%. The overall
sensitivity, specificity and accuracy for the detection of
mesorectal nodal metastases reported are 64-80%, 92-98%
and 88-95%, respectively [86–90]. The reported sensitivity
and specificity for 3 T are very similar to the corresponding
figures mentioned above for 1.5 T. The high signal of 3 T
can, however, be used for thinner slice 3D T2-weighted
imaging.
Coils
Body coil MRI has shown T- and N-stage accuracy ranging
from 59% to 95% and 39% to 95%, respectively. Endorectal
coil MRI has shown improved T- and N-stage accuracy, with
rates of 66% to 91% and 72% to 79%, respectively [91, 92].
While endorectal coils have comparable accuracies to
endorectal ultrasound for distinction among T1-3 stages
[93, 94], the diagnostic accuracy of these coils for
demonstration of involvement of the mesorectal fascia would
not be sufficient. Some authors have used a combination of
both surface and endorectal coils, yet pelvic MRI after the
placement of endorectal coil in addition to the phased-array
coil has not been superior to the imaging with phased-array
coil alone in the T-staging of rectal carcinomas [95]. Surface
coils are easy to position and do not have the problems of
endorectal coils. Furthermore, the most important piece of
information, namely, involvement of the mesorectal fascia, is
demonstrated easily with surface coils [96]. At present,
phased-array MRI best fulfils the clinical requirements for
preoperative staging of rectal cancer [97].
Tumour status after preoperative treatment
Several studies have evaluated MRI after and sometimes
also during preoperative treatment. In the following, we use
the term MRI2 for MRI performed after or during neo-
adjuvant treatment as opposed to MRI1, which is per-
formed before therapy. The aims of studies concerning
MRI2 could be summarised as the following:
1. Comparison between MRI2 and histopathology or
between MRI2 and MRI1
2. Can MRI2 help change treatment?
Table 1 Different imaging planes
Plane Advantage Disadvantage Usage
Sagittal (orthogonal) Easy for measuring tumor height and length.
Best for assessment of involvement of
midline organs and structures
Structures slightly lateral to midline not




Axial (orthogonal) Easily recognizable by clinicians. Easy for
comparison with MRI or other imaging
modalities, especially comparison of lymph
nodes. Often best view of inguinal lymph
nodes
Due to funnel-shaped form of pelvic
floor and anterior curve of
rectosigmoid, not enough for
adequate detailed analysis in many cases
Easily reproducible.
Recommended
Coronal orthogonal None Takes time of more important images Not recommended
Semi-coronally
parallel to anal canal
Visually informative for surgeons in low
rectal tumors





Provides best differential of T1, T2 and
minimal T3. Has to be repeated at all areas
where distinction between T3 and T1-2 is
important
Needs either capable technicians or




to anterior mesorectal fascia
For anterior tumors or tumors with anterior
component, especially in female subjects
Sometimes not necessary in cases of






For tumors growing dorsally and laterally
close to pelvic floor. Can provide coverage
of mesorectal lymph nodes




Most important plane for low tumors at the
level of pelvic floor or lower down
Not essential for tumors completely
above the pelvic floor
Not essential for
tumors completely
above the pelvic floor
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Aim 1 is chiefly academic, and does not influence
treatment directly like aim 2.
Aim 1, comparison between MRI2 and histopathology
or between MRI2 and MRI1: most tumours decrease in
size being replaced by fibrosis with mucin pools [98–101],
and studies on MRI2 have shown that the degree of
tumour volume reduction correlates with tumour regres-
sion mainly based on a histopathological classification
proposed by Dworak et al. [102]. Tumours that histopath-
ologically respond have a good prognosis, particularly if a
complete response (pCR) is seen [103]. It is, however, not
entirely clear which staging (MRI1, MRI2 or postopera-
tive histopathology) provides the best diagnostic and
prognostic information. Though one study claims that
MRI before treatment correlates better with prognosis and
local recurrence than histopathology after preoperative
treatment [104], the TNM staging after treatment still has
prognostic value [105]. Unfortunately, as MRI2 is a
relatively new concept its prognostic value has not been
validated, especially because it is done only in a subset of
patients and with different protocols.
Most radiological studies have concentrated on the
correlation between MRI2 and histopathology and have
shown moderate correlation varying between 67 and 84%
[106–109], being worst for mucin-producing tumours
(Fig. 15). The basis of most of these has been tumour
volume measurements [110, 111].
Perfusion studies have been used for differentiation
between viable and non-viable malignant cells based on
microcirculation [112–114]. The basis of these observations
is that viable tumours have increased and rapid blood flow,
while fibrosis, necrosis and mucin pools, on the other hand,
have slower perfusion. These studies have not found their
way into clinical routine because of the complexity of the
measurements [115], and not all investigators have repro-
duced the previous results [116, 117].
DWI also changes with successful treatment as a result of
decreasing cell density from abundant tumour cells to
fibrosis and mucin pools, and changes in cell shape and
size. It is not clear, however, which diffusion coefficient
value is more important, the one measured at MRI1, at
MRI2 or at the change from MRI1 to MRI2 [86]. More on
DWI is provided below.
The abovementioned retrospective studies show that there
are large and considerable overlaps between MRI2 values
and different degrees of histopathological regression. Also, if
MRI2 proved to provide more valuable information than
histopathology, its use would be increased. To our knowl-
edge, there is as of yet no prospective study comparing the
prognostic value of MRI1 vs MRI2 vs histopathology, and
this should probably be an aim of future studies.
Aim 2, treatment modification: if a tumour responds in
such a way that surgical treatment can be altered or in
practice is less extensive than primarily decided upon based
on MRI1, then MRI2 is indicated (Figs. 16, 17). The





No surgery (wait and see or watchful waiting) can be
offered to patients with no residual remaining tumour (or
contraindication/refusal of surgery) [118]. Local excision
can be offered to those patients with limited luminal disease
[119, 120]. Both these approaches, collectively termed
“organ preservation”, require adequate assessment of
mesorectal lymph nodes as well (Table 2).
Fig. 15 Mucin-producing
tumours are particularly difficult
to evaluate after neo-adjuvant
treatment. The difference
between sagittal TSE images
before (a) and after treatment
(b) (1.5 T) can only be seen in
findings such as mucosal
oedema of the lower rectum
(white arrow), and presacral
oedema (black arrow). The
tumour itself and it extension
outside the rectum (hatched
arrows) are virtually unchanged
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Table 2 describes in brief how surgical treatments of
patients could change based on information obtained at
MRI2. One should remember that early tumours do not
require long-term neoadjuvant therapy and therefore no
MRI2.
In order to change treatment from extended TME to
limited or no surgery, two requirements should be met:
1. MRI can distinguish between ypT0 (where no surgery
is needed), small ypT1 (where local excision can be
Fig. 16 Extensive large tumour
(white arrow) on sagittal TSE
(a) and axial TSE (b) images
(1.5 T). The tumour extends to
several important structures
(dotted arrows). After neo-
adjuvant treatment, on TSE im-
aging (c, d) the tumor has
shrunk considerably. The exten-
sion to nearby structures
remains unaltered on the TSE
image. Surgery therefore cannot
be limited based on imaging
after neo-adjuvant therapy
Fig. 17 Axial TSE images
(1.5 T) of a large tumour (white
solid arrow) before (a) and after
(b) neo-adjuvant therapy. The
tumour has shrunk tremendous-
ly, yet the extension to the
uterus (dotted white arrow), the
fasciae (black solid arrows) and
the small intestine (dotted black
arrows) are visible in the form
of low-signal bands. The bands
are composed of fibrosis, yet
based on MRI, it is difficult to
negate remaining tumour in the
fibrotic strands
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considered) and tumours larger than small ypT1-ypT2
(where TME should be considered) [121, 122].
2. In addition, MRI2 should detect disappearance of all
extramural malignant metastases and lymph nodes.
In one study of restaging irradiated tumours, MRI2 had
an accuracy of 52% in T-staging and 68% in N-staging.
Poor agreement between post-combined chemo-
radiotherapy MRI2 and pathological staging was observed
in both T- (k=0.017) and N-staging (k = 0.031). Most of the
inaccuracy in T- and N-staging is caused by over-staging
[123]. The problem with MRI is believed to be that it
cannot completely differentiate fibrosis from viable residual
tumours. Though fibrosis shows lower signal than tumour
on T2-weighted imaging, there is still considerable overlap
between normal viable tumour tissue and fibrosis (Fig. 18)
[124]. In a recent retrospective study [111], the authors used
a combination of tumour volume reduction rate and original
tumour volume to predict ypT0-2 in 67 patients. They found
that with an initial tumour volume of ≤50 cm3 at MRI1 and a
reduction rate ≥75%, the excised tumour was always ypT0-2.
Figures 17 and 18 both demonstrate these cases. Tiny strands
and smooth slight thickening of fascia with very low signal
on T2-weighted imaging are most commonly associated with
absence of tumour at histopathology.
This is an interesting development; however, it cannot
help distinguish scenario A from other scenarios. However,
at the European Society of Gastrointestinal and Abdominal
Radiology (ESGAR) meeting in 2009 and the ECR meeting
2010 some preliminary promising results from one multi-
centre study were unveiled (congress proceedings and Dr.
Beets-Tan, personal communication). The approach was
offering surveillance with endoscopy and follow-up MRI
instead of surgery (wait-and-watch approach) if no tumour
residue could be detected. DWI should be used in addition
and the absence of any tumour signal has shown to improve
Table 2 Possible treatment modifications based on MRI after neoadjuvant therapy (MRI2) and its requirements. For discussion of different
scenarios please refer to the text
Planned surgery after neoadjuvant therapy





on initial MRI (MRI1)
TME Scenario A;
requires:
Scenario B; no added clinical value of
MRI2








Scenario D; requires MRI2 to distinguish
reliably that fibrosis outside mesorectum
can be left alone
Scenario E; relevant only if pattern of
extension to organs outside
mesorectal fascia changes
Fig. 18 Axial (a), sagittal (b) and axial (c) TSE images (1.5 T) of a
rectosigmoid cancer after neoadjuvant therapy. There is remaining
thickening of the peritoneal reflection (white arrows) and low signal
infiltration (black arrows) in the perirectal fat. No tumour signal has
returned. The tumour was a T1 at histopathology
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the accuracy of diagnosis of complete response to approx-
imately 80% (ECR 2010).
Aside from T-staging, the status of the lymph nodes
remains unclear [125], and some studies have found poor
results when lymph nodes are staged after neoadjuvant
therapy and compared with histopathology [126]. This
group found a significant difference in node positivity
between MRI and pathological staging (P=0.005). Another
study looked at matched lymph nodes after treatment and
found that the most reliable predictors for identifying
Fig. 19 Axial (a) and parasagit-
tal (b) TSE images (1.5 T) of a
tumour recurrence (arrows). The
tumour is an expansive mass
located asymmetrically in front
of the sacrum, lying against the
piriformis muscle (black arrow)
and the pelvic floor dorsally
(dotted arrow)
Fig. 20 Axial images (1.5 T) with T2-weighted image with fat
saturation (a), and T1-weighted image after contrast enhancement
with fat saturation (b). The tumour is barely visible in a, and more
clearly in b. Axial high-resolution TSE, however, depicts the tumour
best, also showing its growth pattern and relation to neighbouring
structures
Insights Imaging (2010) 1:245–267 261
benign nodes were obtained after using USPIO [127].
There are two major problems with application of the
results of this study into everyday practice:
1. Unavailability of USPIO as detailed before
2. The study concerns matched lymph nodes and not all
lymph nodes
Our own experience, and that of others, however, is that
small lymph nodes on MRI1 disappear completely on
MRI2, and the absence of any visible lymph nodes on T2-
weighted imaging and DWI at MRI2 is almost always
reported as N0 at histopathology. In summary, 4-25% of
patients can respond with a pathologically complete
response locally, and this may change the role of MRI
before surgery, or perhaps follow-up MRI [128].
There are only anecdotes of tumour progression under
treatment reported and seen only when a tumour ruptures or
treatment is withheld because of some complications (e.g.
myocardial infarction). In an unpublished study of 99 MRI2
and their comparison with MRI1, there were no cases of
progression (Torkzad et al., personal communication).
In a patient with tumour extending outside the
mesorectal fascia at MRI1 and no signs of growth
towards the mesorectal fascia at MRI2, less extensive
surgery could possibly be an option [99]. This study did
not show any additional value for MRI2 compared with
MRI1. The main reason is that MRI cannot rule out
remaining tumour cells in remaining fibrosis [110]. Our
experience, and that of others, however, is that if all
tumour tissues reaching the mesorectal fascia and beyond
are replaced by only very thin spiculations with very low
signal intensity on T2-weighted imaging, the likelihood of
tumour being found at histopathology is not high. Some
surgeons use this for limiting their surgery to standard
TME and not removing other organs. Other surgeons may,
however, be reluctant to leave fibrosis extending to
neighbouring organs at surgery.
Different forms of therapy might induce different
imaging findings at different time periods, an issue that
has not been addressed adequately in the literature.
Ongoing response to chemo-radiotherapy has been reported
for up to 12 weeks post-treatment, which has important
clinical implications regarding the most appropriate time to
operate or perform MRI2 [129].
In summary, the importance of MRI2 has been limited
thus far for clinical use in the individual patient. This could
change in the future, however, pending newer studies and
newer methods. Certainly not all patients need MRI2. We
have to define and study the following:
1. When is the optimal timing of MRI2?
2. What is the optimal imaging method for MRI2?
3. Which patients need MRI2?
4. What gives the best prognostic information, MRI1,
MRI2 or histopathology?
5. How can treatment plans be changed based on MRI2?
Local recurrence
The imaging indications in local recurrence are to verify or
identify local recurrence, and to assess the extent of the
local recurrence. Owing to improved treatment strategies,
the prognosis in rectal cancer has improved dramatically,
with rectal cancer now having a better prognosis than colon
cancer [130]. MRI is used widely for diagnosis and surgical
planning when recurrence is suspected [131, 132].
The local recurrence rate has decreased greatly. In the post-
TME era, most recurrences occur at the anastomotic site,
presacrally or at the level of the pelvic floor, with very few at
the lateral pelvic side walls in the European material (Fig. 19)
[133, 134]. The best sequence for imaging is TSE, although
contrast enhancement can be useful at times (Fig. 20).
Pelvic surveillance by MRI does not seem justified as
part of routine follow-up after a curative resection for rectal
cancer and should be reserved for selective imaging of
patients with clinical, colonoscopic and/or biochemically
suspected recurrent disease [135–141].
Conclusion
Magnetic resonance imaging is a valuable tool for the
planning of treatment in rectal cancer. It is the single most
important technique in the local staging of patients with
rectal cancer. MRI provides reliable risk allocation for
different patient groups, helping to choose different
treatment regimens in the context of multidisciplinary
meetings with a common terminology [132]. The MR
techniques are continuously improving, and as there are
several limitations in rectal cancer staging, especially for
lymph node staging, we can foresee improvements. The
role of MRI after preoperative treatment has to be defined
and evaluated. Finally, MRI has proven its role in patients
with local recurrence.
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